Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Orexigen Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.83 Insider Own0.10% Shs Outstand122.53M Perf Week-7.52%
Market Cap497.47M Forward P/E- EPS next Y-0.39 Insider Trans81.45% Shs Float121.58M Perf Month0.50%
Income-89.50M PEG- EPS next Q-0.03 Inst Own79.10% Short Float31.11% Perf Quarter-18.64%
Sales3.40M P/S146.32 EPS this Y37.00% Inst Trans-3.86% Short Ratio9.11 Perf Half Y-29.27%
Book/sh0.00 P/B- EPS next Y-30.00% ROA-63.40% Target Price11.00 Perf Year-16.80%
Cash/sh1.09 P/C3.73 EPS next 5Y14.50% ROE-389.10% 52W Range3.11 - 7.82 Perf YTD-27.89%
Dividend- P/FCF- EPS past 5Y21.90% ROI-63.30% 52W High-48.08% Beta2.40
Dividend %- Quick Ratio5.70 Sales past 5Y102.40% Gross Margin- 52W Low30.55% ATR0.30
Employees50 Current Ratio5.70 Sales Q/Q0.00% Oper. Margin- RSI (14)43.33 Volatility7.41% 8.07%
OptionableYes Debt/Eq163.80 EPS Q/Q-10.50% Profit Margin- Rel Volume0.43 Prev Close4.13
ShortableYes LT Debt/Eq163.80 EarningsNov 10 BMO Payout- Avg Volume4.15M Price4.06
Recom1.70 SMA202.28% SMA50-13.79% SMA200-29.33% Volume1,767,259 Change-1.69%
10-Jan-14Initiated WallachBeth Buy $9
03-Oct-13Initiated Cowen Outperform $10
21-Sep-11Upgrade JMP Securities Mkt Perform → Mkt Outperform $5
01-Feb-11Downgrade JMP Securities Mkt Outperform → Mkt Perform
01-Feb-11Downgrade Canaccord Genuity Buy → Hold
03-Dec-10Downgrade Rodman & Renshaw Mkt Perform → Mkt Underperform
16-Jul-10Reiterated JMP Securities Mkt Outperform $16 → $13
16-Jul-10Downgrade Rodman & Renshaw Mkt Outperform → Mkt Perform
02-Feb-10Initiated Jefferies & Co Buy $12
24-Jun-09Initiated Rodman & Renshaw Mkt Outperform $14
13-Mar-09Reiterated Lazard Capital Mkts Buy $13 → $10
03-Apr-08Initiated Cowen & Co Outperform
06-Feb-08Initiated Lazard Capital Buy
04-Feb-08Reiterated Canaccord Adams Buy $29 → $32
03-Jan-08Initiated JP Morgan Overweight
03-Oct-07Upgrade JMP Securities Mkt Outperform → Strong Buy $26
07-Jun-07Initiated JP Morgan Overweight
06-Jun-07Initiated JMP Securities Mkt Outperform $26
31-Oct-14 08:30AM  Orexigen Announces Contrave® (naltrexone HCI and bupropion HCI extended release) Data Presentations at the ObesityWeek Meeting in Boston PR Newswire
22-Oct-14 07:32AM  Orexigen (OREX) Shows Strength: Stock Gains 11.1% Zacks
20-Oct-14 08:00AM  Takeda and Orexigen Announce Availability of CONTRAVE® (naltrexone HCI and bupropion HCI) Extended-Release Tablets for Chronic Weight Management in Obese Adults PR Newswire
16-Oct-14 01:25PM  Orexigen Up on $100M Milestone Payment from Takeda Zacks +5.28%
15-Oct-14 04:27PM  AbbVie and Bank of America are big market movers AP +15.03%
04:01PM  Shire PLC Takes A Dive As AbbVie Reconsiders Offer at TheStreet
08:30AM  Milestone Payments Earned by Orexigen Total $100 Million as Contrave® (naltrexone HCI and bupropion HCI extended release) is Shipped to Wholesalers in Preparation for Commercial Launch PR Newswire
18-Sep-14 08:25AM  The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead Zacks
17-Sep-14 02:00PM  Biotech Stock Roundup: Avanir Soars on Phase II Data, Orexigen's Contrave Approved Zacks
16-Sep-14 04:15PM  Orexigen Therapeutics to Present at the Bank of America Merrill Lynch Global Healthcare Conference PR Newswire
10:30AM  Insider Trading Alert - HTGC, OREX And TEP Traded By Insiders at TheStreet
15-Sep-14 06:00AM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online -5.43%
05:51AM  Selling Obesity Drugs to Americans Shouldn't Be This Hard at BusinessWeek
12-Sep-14 04:10PM  Novo Nordisk's Saxenda Gets Positive Opinion for Obesity Zacks
01:20PM  Nasdaq stocks posting largest percentage decreases AP
11:00AM  [video] Orexigen's anti-obesity pill wins FDA Approval at CNBC
11-Sep-14 05:23PM  FDA panel backs Novo Nordisk injection for obesity AP -10.51%
05:15PM  [video] Orexigen drops in spite of FDA approval at CNBC
04:10PM  How Will Orexigen Therapeutics (OREX) Stock Respond to FDA's Contrave Approval? at TheStreet
04:00PM  U.S. FDA panel: Novo Nordisk's liraglutide safe/effective for obesity Reuters
03:30PM  Orexigen's Obesity Drug Contrave Approved by the FDA Zacks
01:49PM  FDA approves weight-loss drug Contrave AP
01:23PM  Orexigen's Obesity Pill is Approved and Stock Falls. Don't be Surprised at TheStreet
01:11PM  [video] Orexigen's obesity pill at CNBC
12:50PM  [$$] FDA Approves Weight-Loss Drug at The Wall Street Journal
10:34AM  Long-awaited diet pill gets U.S. approval Reuters
08:30AM  Orexigen Therapeutics Call scheduled for 8:30 am ET today CCBN
07:40AM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Other Events EDGAR Online
07:00AM  Takeda and Orexigen Announce FDA Approval of Contrave® (naltrexone HCI and bupropion HCI) Extended-release Tablets for Chronic Weight Management PR Newswire
10-Sep-14 09:16PM  New Drug to Treat Obesity Gains Approval by F.D.A. at New York Times
07:58PM  FDA Approves Contrave Weight Loss Drug From Orexigen And Takeda at Forbes
07:46PM  Orexigen Therapeutics to Host Conference Call and Webcast At 8:30 AM Eastern Time September 11, 2014 PR Newswire
07:00PM  Orexigen Wins U.S. FDA Approval for Weight-Loss Pill at Bloomberg
08-Sep-14 05:15PM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement EDGAR Online
02-Sep-14 08:00AM  Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent PR Newswire
19-Aug-14 10:45AM  You've got obesity all wrong: Zafgen CEO at CNBC
15-Aug-14 01:04PM  OREXIGEN THERAPEUTICS, INC. Financials EDGAR Online Financials
08-Aug-14 05:13PM  OREXIGEN THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report EDGAR Online
08:20AM  Orexigen Therapeutics Reports Wider Q2 Loss as Costs Mount Zacks
07-Aug-14 08:00AM  Orexigen Therapeutics Inc Earnings Call scheduled for 8:00 am ET today CCBN
07:20AM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a EDGAR Online
07:07AM  Q2 2014 Orexigen Therapeutics, Inc. Earnings Release - Before Market Open CCBN
07:00AM  Orexigen Therapeutics Reports Corporate and Financial Results for the Second Quarter Ended June 30, 2014 PR Newswire
31-Jul-14 08:00AM  Orexigen Therapeutics to Host Second Quarter 2014 Financial Results Conference Call and Webcast PR Newswire
30-Jul-14 01:21PM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Other Events EDGAR Online
08:00AM  Orexigen Receives CHMP Day 180 List of Outstanding Issues PR Newswire
21-Jul-14 09:46AM  Perilous Reversal Watch: Orexigen Therapeutics (OREX) at TheStreet
19-Jul-14 04:14PM  The Implications of Obesity as a Disability in Europe at Motley Fool
18-Jul-14 10:09AM  Trade-Ideas: Orexigen Therapeutics (OREX) Is Today's "Dead Cat Bounce" Stock at TheStreet +5.56%
05:47AM  Call buyers returning to Orexigen optionMONSTER
15-Jul-14 06:50PM  Arena Pharmaceuticals Inc. Still Down After CEO's Sale at Motley Fool
11-Jul-14 01:01PM  Arena Stock Holds On Expected Dip In Sales - Bottom May Be In at Seeking Alpha
06:14AM  Bull throws weight behind Orexigen optionMONSTER
10-Jul-14 11:54AM  14 Insanely Important Biotech/Drug Trading Catalysts for the Rest of 2014 at TheStreet
03-Jul-14 04:11PM  3 Stocks Even Volatility-Loving Nasdaq Investors Hate at Motley Fool
04:06PM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Subm EDGAR Online
01-Jul-14 06:09PM  The Next Orphan Drug Multibagger and Future Obesity Champion? at Motley Fool
27-Jun-14 05:30PM  Are Investors Wrong About Orexigen Therapeutics? at Motley Fool
05:01PM  3 Biotech Stocks with Catalysts Incoming: Spectrum, Orexigen, and Avanir at Motley Fool
25-Jun-14 05:30PM  Are Investors Wrong About VIVUS? at Motley Fool
24-Jun-14 06:20AM  How Bad Is This Delay for Orexigen Therapeutics, Inc? at Motley Fool
20-Jun-14 11:34AM  The Anti-Obesity Space Is Not As Simple As Some Think at Seeking Alpha
03:19AM  Now Available: Shares in Zafgen, the Best Obesity Drugmaker to Date at Motley Fool
19-Jun-14 03:12PM  Why Zafgen Inc. Shares Roared Higher at Motley Fool
07:24AM  The Zacks Analyst Blog Highlights: Idenix, Achillion Pharmaceuticals, Nektar, Orexigen, Celgene, Alexion and Biogen Zacks
18-Jun-14 09:33AM  Biotech Stock Roundup: HCV Back in Focus - Idenix, Achillion Soar Zacks
17-Jun-14 07:41AM  Orexigen (OREX) in Focus: Stock Moves 7.5% Higher Zacks
16-Jun-14 04:19PM  What Will It Take For Arena Stock To Rise? at Seeking Alpha +7.52%
08:00AM  3 Stocks Crushed by the Market This Week at Motley Fool
15-Jun-14 11:20AM  This Week in Biotech: Actions Speak Louder Than Words at Motley Fool
13-Jun-14 05:32PM  Is It Time to Buy Orexigen? at Motley Fool
02:56PM  Vivus Suit Preserves Exclusivity Of Qsymia - For Now at Seeking Alpha
02:49PM  Arena's Belviq Sales Do More Than Recover at Seeking Alpha
08:30AM  Orexigen Therapeutics to Present at the Wells Fargo Securities 2014 Healthcare Conference PR Newswire
06:04AM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online
12-Jun-14 05:30PM  Orexigen Slumps as Obesity Drug Approval Delayed Zacks
Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical product candidates for the treatment of obesity. Its product candidates include NB32, which has completed Phase III clinical trials and is being studied in a cardiovascular outcomes trial; and Empatic that has completed Phase II clinical trials. Orexigen Therapeutics, Inc. has collaboration agreement with Takeda Pharmaceutical Company Limited to develop and commercialize NB32 in the United States, Canada, and Mexico. The company was founded in 2002 and is headquartered in La Jolla, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Turner Heather DVP, Gen. Counsel & SecretarySep 22Option Exercise1.66300,000498,000300,000Sep 22 06:49 PM
Turner Heather DVP, Gen. Counsel & SecretarySep 22Sale4.47300,0001,339,5000Sep 22 06:49 PM
Hagan Joseph PSr. VP, Corporate DevelopmentSep 15Buy4.695,00023,45013,026Sep 15 03:11 PM
NARACHI MICHAELPresident and CEOSep 15Buy4.7850,000239,10058,026Sep 15 02:41 PM
DOVEY BRIAN HDirectorApr 22Option Exercise0.004,691,4704,6917,580,065Apr 23 05:15 PM